Research scope: This page is for qualified laboratory and in-vitro research only. It contains no dosing, administration, medical, human-use, or veterinary-use guidance.
What the name usually describes
A commercial three-component preparation combining TB-500-labeled material, BPC-157, and KPV.
Also marketed as: TB-500 + BPC-157 + KPV.
Formula and component amounts can differ by supplier and over time. The product label, finished-lot report, and exact molecular identities control—not the blend nickname.
Evidence boundary
The Coremend name is supplier-specific. Component-level preclinical studies do not establish evidence for the exact co-formulation.
A study of one constituent does not demonstrate synergy, stability, safety, or any claimed outcome for a co-lyophilized mixture.
Finished-blend documentation checks
- Require the identity and stated mass of every component—not only a total vial mass or a single HPLC area result.
- Confirm whether testing was performed on the finished co-formulated blend or inferred from separate ingredient records.
- Record the exact formula, component ratio, lot number, report date, methods, and supplier because the marketing name alone is not a chemical specification.
Research starting points
Review the individual component pages before evaluating a blend:
TB-500 / thymosin-beta-4-related material
BPC-157
KPV